EUVIMEDEUVIMED entdecken
Crossref

CD13 as a potential theranostic target for prostate-specific membrane antigen-negative prostate cancer and first-in-human study of [18F]AlF-CD13-L1 PET/CT imaging

Wei Tang iD, Ming Zhou, Chenxi Lu, Lin Qi, Ye Zhang iD, Yongxiang Tang iD, Xiaomei Gao iD, Shuo Hu iD, Yi Cai iD

European Journal of Nuclear Medicine and Molecular Imaging · 2025

DOI: 10.1007/s00259-025-07140-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2025. Verfasst von Wei Tang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Disorders of Prostate Cancer Multidisciplinary Team, National Clinical Research Center for Geriatric Disorders, Xiangya Hospit…. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Prostatic Neoplasms, Glutamate Carboxypeptidase II, CD13 Antigens. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: Outstanding Youth Fund Project of Hunan Province, Clinical Research Foundation of the National Clinical Research Center for Geriatric Diseases (XIANGYA), National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Approximately 10% of prostate cancer (PCa) are prostate-specific membrane antigen (PSMA)-negative, leading to blind spots in PSMA-based diagnosis. This study aimed to identify a potential target for PSMA-negative PCa and preliminarily evaluate the feasibility of using radionuclide probe targeting the identified target for PCa diagnosis. METHODS: Quantitative protein analysis was performed on eight PSMA-negative PCa and eleven controls to identify a potential molecular target, followed by validation with an expanded cohort using immunohistochemistry. Sixteen participants underwent [18F]AlF-CD13-L1 PET/CT scanning, with the PCa pathological tissues used as references to interpret the imaging results. RESULTS: Quantitative protein analysis revealed CD13 as the most significantly upregulated membrane protein in PSMA-negative PCa. Expanded validation results indicated that CD13 positivity rates were 92.9% (13/14), 82.7% (105/127), 91.7% (11/12), and 70% (14/20) in PSMA-negative PCa, PSMA-positive PCa, ductal adenocarcinoma of the prostate (DAC), and intraductal carcinoma of the prostate (IDC-P), respectively. In PCa participants, the median [18F]AlF-CD13-L1 PET/CT maximum standardized uptake value (SUVmax) of tumors and tumor-to-muscle ratio were 4.3 (1.5-5.8) and 4.6 (1.7-6.1), respectively. The SUVmax value of the PCa lesions and the tumor-to-muscle ratio showed a positive correlation with the immunohistochemical score of CD13 of the PCa lesions (rspearman = 0.6249, p = 0.025; rspearman = 0.6714, p = 0.015, respectively), with CD13-positive tumors showing significant radiotracer accumulation. CONCLUSION: CD13 was a potential target for PSMA-negative PCa and also showed high positivity rates in PSMA-positive PCa, DAC, and IDC-P. [18F]AlF-CD13-L1 selectively accumulated in CD13-positive PCa, enabling visualization. (Trial registration: ChiCTR2300077817. Registered November 21, 2023).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Positron Emission Tomography Computed TomographyProstatic NeoplasmsGlutamate Carboxypeptidase IICD13 AntigensTheranostic NanomedicineHumansMaleAgedMiddle AgedAntigens, SurfaceFluorine Radioisotopes

Stichwörter der Autor:innen

CD13 antigensClinical trialFOLH1 proteinPositron emission tomography computed tomographyProstatic neoplasms

Substanzen

Glutamate Carboxypeptidase IICD13 AntigensFOLH1 protein, humanAntigens, SurfaceFluorine Radioisotopes

Autor:innen und Institutionen

  • Department of Urology, Disorders of Prostate Cancer Multidisciplinary Team, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China.
  • Department of Nuclear Medicine, Disorders of Prostate Cancer Multidisciplinary Team, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China.
  • Department of Oncology, NHC Key Laboratory of Cancer Proteomics, Disorders of Prostate Cancer Multidisciplinary Team, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University…
  • Department of Nuclear Medicine, Disorders of Prostate Cancer Multidisciplinary Team, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China. xyyf0401@qq.co…
  • Department of Pathology, Disorders of Prostate Cancer Multidisciplinary Team, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China. lswindy_2012@163.com.
  • Department of Nuclear Medicine, Disorders of Prostate Cancer Multidisciplinary Team, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China. hushuo2018@163…

ORCID-Profile: Wei Tang, Ye Zhang, Yongxiang Tang, Xiaomei Gao, Shuo Hu, Yi Cai

Förderung

  • Outstanding Youth Fund Project of Hunan Province
  • Clinical Research Foundation of the National Clinical Research Center for Geriatric Diseases (XIANGYA)
  • National Natural Science Foundation of China
  • Key Research and Development Program of Hunan Province
  • Key Program of Ministry of Industry and Information Technology of China
  • Science and Technology Innovation Program of Hunan Province
  • National Key Research and Development Plan
  • Clinical Big Data System Construction Project Fund of Xiangya Hospital

Zitieren

APA

Tang, W., Zhou, M., Lu, C., Qi, L., Zhang, Y., Tang, Y., Gao, X., Hu, S., & Cai, Y. (2025). CD13 as a potential theranostic target for prostate-specific membrane antigen-negative prostate cancer and first-in-human study of [18F]AlF-CD13-L1 PET/CT imaging. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-025-07140-2

Vancouver

Tang W, Zhou M, Lu C, Qi L, Zhang Y, Tang Y, et al. CD13 as a potential theranostic target for prostate-specific membrane antigen-negative prostate cancer and first-in-human study of [18F]AlF-CD13-L1 PET/CT imaging. European Journal of Nuclear Medicine and Molecular Imaging. 2025. doi:10.1007/s00259-025-07140-2

BibTeX
@article{Tang2025,
  author = {Tang, Wei and Zhou, Ming and Lu, Chenxi and Qi, Lin and Zhang, Ye and Tang, Yongxiang and Gao, Xiaomei and Hu, Shuo and Cai, Yi},
  title = {CD13 as a potential theranostic target for prostate-specific membrane antigen-negative prostate cancer and first-in-human study of [18F]AlF-CD13-L1 PET/CT imaging},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2025},
  doi = {10.1007/s00259-025-07140-2}
}
Kostenlos starten →